中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2014年
2期
123-127
,共5页
储磊%张霞军%王国忠%周文俊%杜忠祥%刘安定%赵宏
儲磊%張霞軍%王國忠%週文俊%杜忠祥%劉安定%趙宏
저뢰%장하군%왕국충%주문준%두충상%류안정%조굉
肝肿瘤%抗Ku86抗体%甲胎蛋白%诊断
肝腫瘤%抗Ku86抗體%甲胎蛋白%診斷
간종류%항Ku86항체%갑태단백%진단
Liver neoplasms%Anti-Ku86 antibody%Alpha-fetoprotein%Diagnosis
目的 探讨Ku86蛋白在肝细胞癌(HCC)组织中的表达及血清抗Ku86抗体在HCC早期诊断中的临床价值.方法 采用Western blot法检测HCC和癌旁正常组织中Ku86蛋白的表达,采用间接酶联免疫吸附试验(ELISA)方法检测HCC、肝硬化患者和正常对照者血清中抗Ku86抗体的水平,采用电化学发光法测定甲胎蛋白(AFP)水平.结果 HCC和癌旁正常组织中Ku86蛋白相对表达最分别为0.21 ±0.05和0.08 ±0.02,差异有统计学意义(P＜0.01).HCC患者、肝硬化患者和正常对照者血清中抗Ku86抗体水平分别为0.47 ±0.22、0.22 ±0.06和0.11 ±0.03,与肝硬化患者比较,HCC患者血清抗Ku86抗体水平显著增高(P＜0.01).HCC组患者中,HBV感染和HCV感染患者血清中抗Ku86抗体水平分别为0.51±0.19和0.47 ±0.24,差异无统计学意义(P =0.267).HCC患者手术前血清抗Ku86抗体水平为0.46 ±0.16,手术后1个月和3个月的血清抗Ku86抗体水平分别为0.35 ±0.13和0.23 ±0.08,手术后血清抗Ku86抗体显著降低(P＜0.01).抗Ku86抗体和AFP鉴别诊断HCC的受试者工作特征曲线下面积分别为0.857和0.739.HCC患者中血清抗Ku86抗体的阳性率为61.4％ (51/83),高于AFP的阳性率(27.7％,23/83).AFP联合抗Ku86抗体检测可将HCC检出率提高至72.3％ (60/83).HCC患者血清中抗Ku86抗体水平与AFP水平无相关性(r=0.156,P =0.161).结论 HCC患者血清抗Ku86抗体水平显著增高,但与HBV、HCV感染无关.抗Ku86抗体可能是早期肝癌的诊断标志物,可与 AFP互补应用于临床.
目的 探討Ku86蛋白在肝細胞癌(HCC)組織中的錶達及血清抗Ku86抗體在HCC早期診斷中的臨床價值.方法 採用Western blot法檢測HCC和癌徬正常組織中Ku86蛋白的錶達,採用間接酶聯免疫吸附試驗(ELISA)方法檢測HCC、肝硬化患者和正常對照者血清中抗Ku86抗體的水平,採用電化學髮光法測定甲胎蛋白(AFP)水平.結果 HCC和癌徬正常組織中Ku86蛋白相對錶達最分彆為0.21 ±0.05和0.08 ±0.02,差異有統計學意義(P＜0.01).HCC患者、肝硬化患者和正常對照者血清中抗Ku86抗體水平分彆為0.47 ±0.22、0.22 ±0.06和0.11 ±0.03,與肝硬化患者比較,HCC患者血清抗Ku86抗體水平顯著增高(P＜0.01).HCC組患者中,HBV感染和HCV感染患者血清中抗Ku86抗體水平分彆為0.51±0.19和0.47 ±0.24,差異無統計學意義(P =0.267).HCC患者手術前血清抗Ku86抗體水平為0.46 ±0.16,手術後1箇月和3箇月的血清抗Ku86抗體水平分彆為0.35 ±0.13和0.23 ±0.08,手術後血清抗Ku86抗體顯著降低(P＜0.01).抗Ku86抗體和AFP鑒彆診斷HCC的受試者工作特徵麯線下麵積分彆為0.857和0.739.HCC患者中血清抗Ku86抗體的暘性率為61.4％ (51/83),高于AFP的暘性率(27.7％,23/83).AFP聯閤抗Ku86抗體檢測可將HCC檢齣率提高至72.3％ (60/83).HCC患者血清中抗Ku86抗體水平與AFP水平無相關性(r=0.156,P =0.161).結論 HCC患者血清抗Ku86抗體水平顯著增高,但與HBV、HCV感染無關.抗Ku86抗體可能是早期肝癌的診斷標誌物,可與 AFP互補應用于臨床.
목적 탐토Ku86단백재간세포암(HCC)조직중적표체급혈청항Ku86항체재HCC조기진단중적림상개치.방법 채용Western blot법검측HCC화암방정상조직중Ku86단백적표체,채용간접매련면역흡부시험(ELISA)방법검측HCC、간경화환자화정상대조자혈청중항Ku86항체적수평,채용전화학발광법측정갑태단백(AFP)수평.결과 HCC화암방정상조직중Ku86단백상대표체최분별위0.21 ±0.05화0.08 ±0.02,차이유통계학의의(P＜0.01).HCC환자、간경화환자화정상대조자혈청중항Ku86항체수평분별위0.47 ±0.22、0.22 ±0.06화0.11 ±0.03,여간경화환자비교,HCC환자혈청항Ku86항체수평현저증고(P＜0.01).HCC조환자중,HBV감염화HCV감염환자혈청중항Ku86항체수평분별위0.51±0.19화0.47 ±0.24,차이무통계학의의(P =0.267).HCC환자수술전혈청항Ku86항체수평위0.46 ±0.16,수술후1개월화3개월적혈청항Ku86항체수평분별위0.35 ±0.13화0.23 ±0.08,수술후혈청항Ku86항체현저강저(P＜0.01).항Ku86항체화AFP감별진단HCC적수시자공작특정곡선하면적분별위0.857화0.739.HCC환자중혈청항Ku86항체적양성솔위61.4％ (51/83),고우AFP적양성솔(27.7％,23/83).AFP연합항Ku86항체검측가장HCC검출솔제고지72.3％ (60/83).HCC환자혈청중항Ku86항체수평여AFP수평무상관성(r=0.156,P =0.161).결론 HCC환자혈청항Ku86항체수평현저증고,단여HBV、HCV감염무관.항Ku86항체가능시조기간암적진단표지물,가여 AFP호보응용우림상.
Objective To investigate the clinical value of serum anti-Ku86 in early detection of hepatocellular carcinoma (HCC).Methods Expression levels of Ku86 protein in HCC and adjacent normal liver tissues were detected by Western blotting.Serum anti-Ku86 level in 83 patients with early HCC and 124 patients with liver cirrhosis were detected by enzyme-linked immunosorbent assay (ELISA).Chemiluminescence was used to measure the serum level of α-fetoprotein (AFP).Results Expression of Ku86 protein in HCC was increased when compared with the adjacent normal liver tissues (0.21 ±0.05 vs.0.08 ±0.02,P ＜0.01).Serum anti-Ku86 level was significantly elevated in HCC patients compared with that in liver cirrhosis patients (0.47 ±0.22 vs.0.22 ±0.06 Abs at 450 nm,P ＜0.01),but there was no significant difference between HBV infection and HCV infection in HCC patients (0.51 ±0.19 vs.0.47 ±0.24,P =0.267).Of note,serum anti-Ku86 level was significantly decreased after surgical resection of the tumors in the 30 HCC cases tested (P ＜ 0.01).The results of ROC analysis indicated a better performance of anti-Ku86 (0.857) than AFP (0.739) for early detection of HCC.In 83 HCC patients,the positive rate of anti-Ku86 was 61.4％ (51/83),significantly higher than that of the AFP positive rate (27.7％,23/83).The anti-Ku86 level was positive in 37 of 60 HCC cases with negative AFP.Combination assay of AFP and anti-Ku86 could detect 60 of 83 HCC cases (72.3％,60/83).There was no significant correlation of antiKu86 and AFP (r =0.156,P =0.161).Conclusions Serum anti-Ku86 level is significantly elevated and is not related to HBV and HCV infection in HCC patients.Serum anti-Ku86 antibody may be a potential biomarker for early detection of HCC,and can be used in combination with AFP in clinics.
